Management
Dr. Paul Reid, PhD
CEO, Director and co-founder of Celtic Biotech
Dr. Paul Reid has a PhD in Neurobiochemistry from Imperial College, London, and BA in Microbiology from Trinity College, Dublin. He is a world-renowned expert in the therapeutic use of snake venom neurotoxins. Formerly president of Receptopharm Inc., a Florida-based company specialising in therapeutic venom technologies, Paul has a wealth of knowledge in biologic therapeutic development and regulatory processes and requirements. He has numerous published papers to his name and several patents issued. Paul is highly experienced in drug production, new drug development, clinical trial design, and experimental design. He is currently based in Florida.
John Reid, MSc
COO, Director and co-founder of Celtic Biotech
John has a master’s degree in international business from Trinity College, Dublin. An experienced business management professional, John established the Company and was responsible for securing initial seed capital and developing key R&D and consultancy agreements. He also coordinated the start-up activities of early funding and angel investments, information dissemination, and liaison with legal, financial, medical, and scientific advisors in Ireland, Europe & the USA. John leads the operational activities of the Company and is based in Ireland where the Company is incorporated.
Dr Dorothy Bray, PhD
Director of Clinical Affairs
Dr. Dorothy Bray has over 25 years of experience in biopharmaceuticals and healthcare management. In the past, she served as a Director of HIV Research and Senior Clinical Program Head of HIV and Opportunistic Infections for GlaxoSmithKline and also as Senior Medical Strategy Head, International Medical Affairs, Glaxo Wellcome Inc, USA and as Principal Clinical Research Scientist at Antivirals, Glaxo Wellcome, UK, and the USA. Dr. Bray has an extensive network of collaborations and contacts with pharmaceutical companies, governments, and non-government organisations in key developed and emerging markets.
David Prestwich, CTA
Chief Finance Officer
David Prestwich is an accountant with specialist experience in M&A tax and UK and international tax structuring matters. He spent several years in the private equity M&A tax teams in KPMG and PwC, working on some of the largest transactions in the market. Skilled in financing & tax strategy and creating tax efficient organisations, David has worked on projects involving business/market innovation, tax innovation, futurology and CSR. He is also experienced in matters of boardroom and corporate governance and, having been part of KPMGs futurology team, David worked with a variety of large multinational groups across all industry sectors on matters of corporate governance, strategic thinking and complex financing.
BOARD OF ADVISORS
Dr. François-Michel Delgado MD
Consultant physician/Medical Oncologist, at the renowned Bizet Clinic in Paris, Dr Delgado was previously Head of Clinical Development at the Oncology Department Rhône-Poulenc, Paris between 1986- 1988. He then took up the position of Medical Director at the Institut de Recherche Pierre Fabre, Boulogne-Billancourt- France later becoming Director of Clinical Development at the Medicament Oncology Department (PFO) Boulogne-Billancourt there from 1998 to 2011. Dr Delgado has also worked alongside Prof. David Khayat as Consultant physician at the Oncology Service at the University Hospital Pitié Salpétrière. Dr Delgado instructed in the Post Graduate Training for Clinical Oncology at the MD Anderson Cancer Center Houston USA and is a member of the European Society of Medical Oncology (ESMO) and the American Society of Medical Oncology (ASCO). Dr Delgado presented the results of Celtic Biotech sponsored Phase I Clinical Studies Parts 1 & 2 at the American Association of Cancer Research (AACR) annual conference in April 2018.
Prof. Zheng Hong Qin, MD, Ph.D.
A professor of pharmacology at the Department of pharmacology in the school of pharmacy of Suzhou University. He received his Ph.D. in pharmacology from Pennsylvania Medical College in 1994. He did his postdoctoral work at the National Institutes of health in the US and later lectured at Harvard University. He is Deputy director of anti-aging Academic Committee of Chinese society of Gerontology and geriatrics, member of biochemical and Molecular Pharmacology Professional Committee, member of neuro and psychopharmacology professional committee, and editorial board member of Chinese Journal of pharmacology. He was selected as China’s most highly cited scholar for five consecutive years in 2014-2018. He is chief scientific collaborator on the development of Celtic Biotech company IP and has been overseeing R&D on behalf of the Company. He has co-authored several papers with Dr. Reid on the mechanism of action of CB-24 and its toxicity against several cancer cell lines, as well as studies on the analgesic properties of the drug.
Prof. John Crown MD
An Irish consultant oncologist and former senator, Prof. Crown's postdoctoral training took place at Guy’s Hospital in London and St. James’s Hospital in Dublin. He completed his training in oncology in New York at Mount Sinai Medical Center and the Memorial Sloan–Kettering Cancer Center. He held the post of assistant professor at Weill Cornell Medical College of Cornell University until 1993 when he returned to Ireland, becoming a consultant at two Dublin hospitals: St. Vincent’s and St. Luke’s. He holds professorships in cancer research from Dublin City University and University College Dublin. Crown has worked to reform cancer treatment in Ireland as chairman of molecular therapeutics for Cancer Ireland, and founder of the Ireland Co-operative Oncology Research Group (ICORG). Prof. Crown guided the initial protocol development of Celtic Biotech's lead candidate, CB-24 in advance of human clinical trials. He became a Member of the Royal Irish Academy on 2021.
Dr. Margit Jeschke
Product IP and Strategy
Currently an independent consultant based in Switzerland. She joined the Scientific Advisory board of Celtic Biotech in 2023. Margit was previously Novartis Global Head of Analytical Stewardship & CMC Correlational Sciences from Sept 2016 – Dec 2021 and her remit also included responsibility for the analytical development strategy of the company’s Cell & Gene Therapy products and analytical chapters of CAR T product regulatory filings. Before this she held the position of Global Head Analytical Development for Cell and Gene Therapy including managing an international team of Analytical Development associates located in the US and Europe. One of Margits key achievements was the BLA approval of KymriahTM , MAA, submitted in Nov 2017 (under orphan designation and with Break Through Therapy and Prime designation). Margit was also onetime Executive Director Novartis Analytical R&D Biologics where she was responsible for all aspects of analytical development and product release of drug substance and finished product for clinical development involving 40+ projects up to BLA/MMA approval including the successful global filing of several Biologics products.
Dr. Maria Angeles Gil-Delgado MD
Consultant Medical Oncologist, Pitié-Salpetriere Hospital, Paris
Previously Head of Clinic at the Oncology Institute of San Sebastian (Spain) and Head of Medical Oncology Department at the Internal Medecine Section of Granada University Hospital. Dr. Gil-Delgado was one time Researcher in charge of the Clinical Trial Bureau of the Institute of Oncology and Immunogenetics, at the University Hospital Paul Brousse (Prof. J.L. Misset) for Phase I, II, III clinical trials: She was involved in the research and evaluation of such new drugs as; mitoxantrone, vinorelbine, THP doxorubicin, fludarabine, pentasosin, vinflunine (Phase I), cetuximab etc. Dr. Gil-Delgado also worked alongside Prof. David Khayat at the Medical Oncology Department at the University Hospital Pité Salpétrière-Paris-France. She is an active member of the European Society of Medical Oncology and the American Society of Medical Oncology. She currently has a private practice at the renowned Clinique Bizet, Paris. Dr. Gil-Delgado oversaw the Celtic Biotech Phase I Part 2 clinical trials.